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The  application  of  physiologically  based  toxicokinetic  (PBTK)  modelling  in  route-to-route  (RtR)  extrap-
olation  of  three  cosmetic  ingredients:  coumarin,  hydroquinone  and  caffeine  is  shown  in this  study.  In
particular,  the oral  no-observed-adverse-effect-level  (NOAEL)  doses  of  these  chemicals  are  extrapolated
to  their  corresponding  dermal  values  by  comparing  the  internal  concentrations  resulting  from  oral  and
dermal  exposure  scenarios.  The  PBTK  model  structure  has been  constructed  to  give  a good  simulation  per-
formance of biochemical  processes  within  the human  body.  The  model  parameters  are calibrated  based
on oral  and  dermal  experimental  data  for the  Caucasian  population  available  in  the  literature.  Particular
attention  is  given  to modelling  the  absorption  stage  (skin and  gastrointestinal  tract)  in the  form  of  several
sub-compartments.  This  gives  better  model  prediction  results  when  compared  to  those  of  a  PBTK  model
with a simpler  structure  of  the  absorption  barrier.  In addition,  the  role  of  quantitative  structure–property
relationships  (QSPRs)  in  predicting  skin  penetration  is  evaluated  for the  three  substances  with  a view  to
incorporating  QSPR-predicted  penetration  parameters  in the  PBTK  model  when  experimental  values  are
lacking. Finally,  PBTK  modelling  is used,  ﬁrst  to extrapolate  oral  NOAEL  doses  derived  from  rat  studies
to  humans,  and  then  to simulate  internal  systemic/liver  concentrations  –  Area Under  Curve  (AUC)  and
peak  concentration  – resulting  from  speciﬁed  dermal  and  oral  exposure  conditions.  Based  on  these  sim-
ulations,  AUC-based  dermal  thresholds  for the  three  case study  compounds  are  derived  and  compared
with  the  experimentally  obtained  oral  threshold  (NOAEL)  values.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Due to concerns about the potentially adverse effects of
uman exposure to cosmetic ingredients, combined with ani-
al  testing and marketing bans under the EU cosmetics
egislation (Parlament and Union, 2009), recent studies are increas-
ngly focusing on the development of predictive models as
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an alternative to animal testing. In particular, physiologically
based toxicokinetic/pharmacokinetic (PBTK/PBPK) models simu-
late concentration–time proﬁles of a parent chemical and its
metabolites in organs and the blood following a compound-speciﬁc
kinetic scenario of absorption, distribution, metabolism and excre-
tion (ADME). These models can be used to ﬁll missing toxicity data
gaps by means of interspecies and route-to-route (RtR) extrapola-
tions. The use of PBTK modelling for RtR extrapolation is based on
comparisons of simulated internal blood or organ concentrations
which are typically characterized by a peak value (Cmax) and area
under curve (AUC) after inhalation, oral or dermal absorption of the
same absolute dose (Chiu and White, 2006; Mielke et al., 2011). In
this way, experimentally determined safe limits such as the oral
ess article under the CC BY-NC-SA license (http://creativecommons.org/licenses/
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Nomenclature
Organ weights
Vorg volume of organ (liv-liver, adp-adipose tissue,
lng-lungs, kid-kidney, git-GI tract (stm-stomach,
SI-small intestine, LI-large intestine), ppt- poorly
perfused tissues, hpt-highly perfused tissues, skn-
skin, ven-venous, art-arterial blood)
f crd cardiac output
forg regional blood ﬂow rates
RBP blood-to-plasma concentration ratio
tappl formulation application time [h]
nf percentage of hair follicles
PCorg tissue-to-blood partition coefﬁcients
Dsc diffusion coefﬁcient in stratum corneum [cm/h]
Dve diffusion coefﬁcient in viable epidermis [cm/h]
Dhf diffusion coefﬁcient in hair follicles [cm/h]
Kp overall permeability coefﬁcient for skin [cm/h]
Kpsc permeability coefﬁcient for stratum corneum [cm/h]
Kpve permeability coefﬁcient for viable epidermis [cm/h]
Jmax maximal ﬂux across skin [mg/cm2/h]
L thickness of skin [cm]
Lve thickness of viable epidermis [cm]
Lsc thickness of stratum corneum [cm]
kaform formulation intake rate from SC [mL/h]
kahf formulation intake rate from hair follicles [mL/h]
Diss dissolution from a matrix formulation (coated
tablet) [L/h]
PCsc partition coefﬁcient stratum corneum/solvent
PCscve partition coefﬁcient stratum corneum/viable epider-
mis
PChf partition coefﬁcient hair follicle/solvent
Area application Area on skin [cm2]
Dt drinking Rate [L/h]
kastm absorption rate into stomach tissue [1/h]
qSC, qVE, ﬂux through stratum corneum, viable epidermis
Cform, Aform concentration and amount of substance in for-
mulation
kmin, kmax kinetic constants of stomach emptying rate to
small intestine [1/h]
kaSI absorption rate from small intestine [1/h]
ﬂowLI ﬂow rate from small intestine into large intestine
[L/h]
kaLI absorption rate from large intestine [1/h]
CLR renal clearance [L/h]
Poct octanol/water partition coefﬁcient
vmax the metabolic rate at maximum (saturating) sub-
strate concentration [mg/h]
km the substrate concentration at which the reaction
rate is half of the maximal [mg/L]
n
t
f
r
e
g
T
(
S
t
s
tKmet First order rate metabolic rate in liver [L/h]
o-observed-adverse-effect-level (NOAEL) dose can be translated
o a dermal or inhalation threshold via toxicokinetic modelling. Dif-
erences in the absorption step (under given exposure conditions)
esult in differences in the internal dose and consequently differ-
nt biological or toxic effects. Since human experimental data are
enerally lacking, there is often a need to scale from animal results.
he common conversion of drug doses to a human equivalent dose
HED) is based on body weight and body surface area (Reagan-
haw et al., 2008). However, this does not take into account all of
he differences in absorption, metabolism and excretion between
pecies. A PBTK model, in contrast, provides a quantitative evalua-
ion of the underlying biological processes, and is therefore a moretters 227 (2014) 189–202
reliable, systems biology driven approach to interspecies extrapo-
lation (Kenyon, 2012).
Three cosmetic ingredients are the subject of this study:
coumarin, hydroquinone and caffeine. Coumarin is used as a fra-
grance and is a natural ingredient of several herbs, beverages,
tobacco and spices. It shows hepatotoxic and carcinogenic prop-
erties mainly in rodents. An oral NOAEL of 10 mg/kg BW/day has
been concluded in the dog. In rats, no-adverse-effect levels for hep-
atotoxic effects ranged from 50 to 130 mg/kgBW/day (EFSA, 2004).
In this study, 50 mg/kg BW/day is taken as the NOAEL in the rat.
Coumarin is extensively metabolized by the liver. There are species-
dependent differences in the pathways for its metabolic conversion.
In humans, it appears that coumarin is extensively metabolized
to 7-hydroxycoumarin (7-HC), and in a smaller amount to 3-
hydroxycoumarin (3-HC), while in the rat and mouse the major
route of metabolism is by a 3,4-epoxidation pathway resulting
in the formation of coumarin 3,4-epoxide which is rearranged
to a toxic metabolite, o-hydroxyphenylacetaldehyde (o-HPA) and
further detoxiﬁed to o-hydroxyphenylacetic acid (o-HPAA) and
o-hydroxyphenylethanol (o-HPE). The construction of simple phys-
iologically based predictive models incorporating the metabolic
pathways of coumarin has already been described in the literature
(Born et al., 2000; Mielke et al., 2011; Rietjens et al., 2008). In these
studies, the RtR extrapolation of a single tolerable daily intake dose
of coumarin (0.1 mg/kgBW) was carried out by comparing the AUC
and Cmax of coumarin in blood and liver. Only dermal AUC of blood
was found to be higher (Mielke et al., 2011).
Hydroquinone is used as a skin whitening agent in creams to
reduce the colour of the skin, in oxidative hair dyes, and in artiﬁcial
nail (manicure) preparations. Repeated oral dosing caused tremors
and reduced activity ((>=64 mg/kg), reduced body weight gain
(>=200 mg/kgBW), convulsions ((>=400 mg/kgBW), and nephropa-
thy in F-344 rats ((>=100 mg/kgBW). An overall rat NOAEL (for all
adverse effects) of 20 mg/kg BW/day was  derived (OECD SIDS, 1996;
Poet et al., 2010). Metabolism to reactive intermediates in the liver
is involved in the renal toxicity and exacerbation of chronic pro-
gressive nephropathy associated with hydroquinone ingestion. The
formation of benzoquinone is the ﬁrst critical step towards the
formation of toxic metabolites. Following oral administration, the
majority of metabolites are conjugates of glucuronic (up to 67%)
and sulphuric (up to 33%) acids (Corley et al., 2000; McGregor,
2007; Poet et al., 2010). Skin enzymes responsible for metabolism of
hydroquinone are reported to have activities ranging from <1% up
to 25% of the activity in the liver (Poet et al., 2010). PBTK model for
hydroquinone has been already used in the literature to compare
human internal dose metrics following oral and dermal exposures
of estimated glutathione conjugates at the applied NOAEL dose
(human equivalent concentration) (Corley et al., 2000; McGregor,
2007; Poet et al., 2010).
Caffeine is found in varying quantities in the seeds, leaves, and
fruit of some plants. It is used in many creams and lotions since
it is believed to slow down the photoaging process of the skin
and to absorb ultraviolet radiation thereby preventing the devel-
opment of tumours after skin exposure to sunlight. It is also used
as an active compound in anti-cellulite products because it pre-
vents excessive accumulation of fat in cells. This alkaloid has potent
antioxidant properties. It increases the microcirculation of blood
in the skin and also stimulates the growth of hair through inhi-
bition of the 5--reductase activity. Recent animal studies have
demonstrated, that depending on the method of administration
and species, the developmental NOAEL in rodents is approximately
30 mg/kgBW/day, the teratogenic NOAEL is 8100 mg/kgBW/day,
and the reproductive NOAEL approximately 80–120 mg/kgBW/day.
In this study, the rat NOAEL of 10 mg/kgBW/day is used (Brent
et al., 2011; OECD SIDS, 2002). Caffeine is metabolized in the liver
to xanthine and uracil derivatives. Paraxanthine is quantitatively
logy Letters 227 (2014) 189–202 191
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Table 1
Physiological parameters for a reference woman and man.
Quantity Reference
woman
Reference man
Average body weight [kg] 65 78
Organ weights fractions (fractions of body weight)
Liver 0.026 0.026
Adipose tissue 0.327 0.213
Lungs 0.0105 0.012
Kidney 0.0044 0.0044
GI tract: 0.0265 0.025
Stomach: 0.00337 0.00318
Small Intestine: 0.0146 0.0138
Large Intestine: 0.0085 0.0080
Poorly perfused
tissues + skin
0.473 0.5855
Highly perfused tissues 0.0676 0.0621
Blood 0.065 0.072
Venous blood 0.04875 0.054
Thickness of: 0.204, 0.0032,
0.0018
0.2906, 0.0047,
0.0017
skin, viable epidermis,
stratum corneum [cm]
Regional blood ﬂow rates [fraction of cardiac output [L/h]
Cardiac output [L/h] 15 BW0.74
Liver 0.25 0.24
Adipose tissue 0.055 0.04
Lungs 0.025 0.025
Kidney 0.19 0.2
Poorly perfused tissues 0.135 0.16
GI tract 0.14 0.13
Fractions of GI tract ﬂow to
stomach, small and large
intestine
0.2, 0.6, 0.2 0.2, 0.6, 0.2
(
(
in propylene glycol was administered to four healthy subjects. Immediately after
dosing, 200 mL  of water was given. Dermal absorption data were taken from Ford
et  al. (Ford et al., 2001). Three male volunteers received a single dermal application
of  ca. 1 mL  of 0.2% solution of 14C-coumarin in 70% ethanol evenly spread on 100 cm2M.  Gajewska et al. / Toxico
he main demethylated product, followed by theobromine and
heophylline, respectively. The metabolism and toxicokinetics of
affeine, and the use of this information in PBTK modelling have
een described in previous studies (Csajka et al., 2005; Ginsberg
t al., 2004; Lelo et al., 1986; Thorn et al., 2012; Zandvliet et al.,
005).
The aims of this study were to determine whether: (a) the
se of sub-compartments in the absorption stage of the PBTK
odel, i.e. the gastrointestinal tract (GI tract) and skin, gives a
etter prediction of blood/plasma levels of selected substances
hen compared to a model of simpler structure; and (b) the
nal model, calibrated using individual and population mean lit-
rature experimental data, can be successfully applied in the
ral-to-dermal extrapolation of toxicity threshold values of three
osmetic ingredients. The oral NOAEL doses determined in rat
tudies were ﬁrst converted to human NOAEL values via simu-
ated internal systemic concentrations following oral absorption.
inally, dermal safe limits were determined based on calculated
rea Under Curve (AUC) and peak concentration (Cmax) for a parent
ompound and its potentially toxic metabolite.The model simu-
ations were performed for single dose applications. This work
oes beyond previously published oral-to-dermal extrapolation
tudies for coumarin and hydroquinone by applying a reﬁned
BTK model in the calculation of oral and dermal safe limits. As
ar as the authors are aware, this is the ﬁrst illustrated use of
BTK modelling for the oral-to-dermal extrapolation of caffeine
oxicity.
. Materials and methods
.1. PBTK model
Three structurally different PBTK models were constructed in order to select one
hat  best simulates ADME processes in human. To distinguish between the mod-
ls, different names are given (PBTK1-3). The schematic representation of the main
rgans considered (Fig. 1) applies to all three models and the differences between
hem are in the GI tract and skin compartments only, as explained in the following
aragraphs.
In PBTK1 the GI tract and skin are represented by one compartment with a ﬁrst
rder rate of absorption, as described in the literature for coumarin and hydro-
uinone (Mielke et al., 2011; Poet et al., 2010; Rietjens et al., 2008).
PBTK2 is applied for dermal absorption only. It consists of the surface com-
artment and two skin compartments with unidimensional diffusion (Fick’s second
aw) across a single skin layer (stratum corneum and viable epidermis are grouped
ogether) into the dermis and there are no hair follicles (Fig. 2).
PBTK3 is the reﬁned PBTK model with various sub-compartments in the skin
nd  GI tract. Depending on the exposure route, multiple sub-compartments are
dded: GI tract with 6 sub-compartments (for oral exposure only, Fig. 3) or skin
ith the surface compartment and 4 skin sub-compartments (for dermal expo-
ure only, Fig. 2). In total, the model with all the sub-compartments consists of
round 20 state variables (organ concentrations) for the parent compound. The
ub-compartments serve to account for the complexity of the absorption process
especially the time-lag in absorption). In the GI tract, three different administra-
ion types are considered: gavage, drinking rate, and dissolution from matrix. A
rst order rate of absorption from stomach, small and large intestine and stomach
mptying rate are included according to Loizou and Spendiff (Loizou and Spendiff,
004). The skin is divided into the stratum corneum, viable epidermis and dermis
ith blood mix. Unidimensional diffusion describes the transport in ﬁne skin and
air follicles according to Fick’s second law with speciﬁed initial and boundary
onditions. The diffusion coefﬁcient is different for the stratum corneum, viable
pidermis and hair follicles. Diffusion via hair follicles is considered for caffeine
nly.
Skin compartments have continuous spatial and temporal concentration gra-
ients, and are described by partial differential equations (PDEs). The other
rgans/bio-ﬂuids such as lungs, liver, kidney, adipose tissue, highly perfused tissues
heart, brain, GI tract – for dermal absorption only, rest of body), poorly perfused
issues (muscle, bone, skin or its part unaffected by absorption) and blood are sin-
le  compartments in the three models. These compartments serve as perfusion and
ccumulation sites. Metabolism is assumed to occur in the liver and skin (for hydro-
uinone only) and excretion via urine and bile (to a lesser extent) is described by
 ﬁrst order rate constant. However, since liver metabolism is the major elimina-
ion route for coumarin, hydroquinone and caffeine, excretion in urine and bile is
ainly considered for their metabolites. The equations for models PBTK1-3 are given
n  Appendix A.Skin 0.05 0.05
Highly perfused tissues 0.155 0.155
The three models are based on the following assumptions:
a) Tissues are homogeneous with respect to the concentration of a chemical. Trans-
port between blood and tissues is assumed to be ﬂow-limited (transport barriers
between free molecules of chemical in blood and tissue are negligible) and equi-
librium between free and bound fractions in blood and tissue is instantaneous.
b)  Inter-individual differences in metabolism and excretion are not explicitly
considered. To partially account for such variations, the metabolic rates are
corrected by the subject’s body weight.
(c) The diffusion coefﬁcients in the stratum corneum, viable epidermis and hair
follicles are assumed constant throughout the skin absorption process. There is
no difference in the mathematical equations describing diffusion in PBTK2 and
PBTK3 models.
The mathematical equations were programmed in R by combining function-
alities of the following R packages: deSolve, ReacTran, PK, FME, rgenoud and
AICcmodavg.1 Ordinary differential equations (ODEs) were solved by the method
lsoda available in the deSolve package, which switches automatically between stiff
and non-stiff methods. The method of lines was used to solve PDEs.
2.1.1. Physiological parameters
All physiological parameters for a reference man  and woman that are indepen-
dent of the chemical and constitute a constant part of the model equations are given
in  Table 1. The values were taken from the Brown study (Brown et al., 1997).
2.1.2. Compound-speciﬁc model parameters and experimental data used for
calibration
2.1.2.1. Coumarin. The physiological and ADME parameters of the rat PBTK model
for oral absorption were taken from Rietjens et al. (Rietjens et al., 2008) and used
unchanged. In vivo data for human oral absorption were taken from Ritschel et al.
(Ritschel et al., 1979, 1977). A single coumarin dose of 0.857 mg/kg BW dissolved1 Available from the Comprehensive R Archive Network website:
http://cran.r-project.org/.
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Fig. 1. General stru
kin area on the back over 6 h of exposure and with 30 min  of ethanol evaporation
occlusion after 30 min).
.1.2.2. Hydroquinone. The physiological and ADME parameters for the rat model
nd human in vivo blood concentrations were taken from Corley et al. (Corley
t  al., 2000). In the latter study, a healthy adult male subject received a single
ose of 275 mg  of hydroquinone in degassed, distilled water at a concentration
f  1.0% (w/w). In the dermal absorption experiment, carried out by Wester et al.
Wester et al., 1998) on four human volunteers, a hydroquinone-containing cream
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Fig. 2. Skin divided into sub-compartments in PBTof PBTK1-3 models.
formulation (2.5 mg hydroquinone in 0.125 g cream) was  placed on a forehead area
of  25 cm2 for 8 h.
2.1.2.3. Caffeine. Rat physiological parameters were taken from Corley et al. (Corley
et  al., 2000), whereas absorption and metabolism parameters were optimized
with respect to blood concentrations from English and Deisinger (English and
Deisinger, 2005). In the latter study, a single dose of 50-mg/kg of hydroquinone was
administered via gavage to Fischer 344 rats and mean results were published.
Three different oral studies in humans were selected for the model calibration and
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alidation. For calibration, plasma concentrations from Lelo et al. (Lelo et al., 1986)
nd  from Csajka et al. (Csajka et al., 2005) were used. In the former study, one non-
moking male volunteer ingested 270 mg  of caffeine in a gelatin capsule whereas in
he  latter study, in addition to a gelatin capsule (200 mg  of caffeine sulphate admin-
stered to 16 subjects), caffeine was applied in the commercial dietary supplement
a mixture containing 200 mg  caffeine and 20 mg  ephedrine alkaloids, administered
o 8 subjects). For model validation, plasma concentrations from the oral study by
ewton et al. (Newton et al., 1981) were selected, in which a gelatin capsule con-
aining 300 mg of caffeine was given to one male subject. To calibrate the model for
ermal exposure, the experiment of Otberg et al. (Otberg et al., 2008) was used, in
hich caffeine in the ethanol/propylene glycol vehicle was  administered to 6 male
olunteers by applying the liquid onto a chest area of 25 cm2 for 24 h. In contrast to
he models for coumarin and hydroquinone, in the case of caffeine, the additional
mpact of hair follicles in the overall absorption process was considered.
The experiments for all the three substances were performed on individuals
n  the fasting state. Tissue-to-blood partition coefﬁcients (PCorg) were either taken
rom the literature (hydroquinone) or calculated (coumarin, caffeine) according to
he  Schmitt method (Schmitt, 2008). In this method, steady state tissue-to-plasma
artition coefﬁcients are calculated based on: a) the composition of the tissues in
erms of water, neutral lipids, neutral and acidic phospholipids, and proteins as
hysiological parameters; and (b) lipophilicity, phospholipid membrane binding,
Ka and the unbound fraction in blood plasma as compound speciﬁc parameters.
.2. Evaluation of the goodness-of-ﬁt of the PBTK models
To compare the performance of the models PBTK1-3, the coefﬁcient of deter-
ination (R2), mean squared error (MSE) and Akaike’s Information Criterion (AIC)
Kletting and Glatting, 2009) were used. For model discrimination, AIC penalizes
odels with a large number of parameters when having the same agreement in
erms of mean squared error. The model with the lowest algebraic AIC therefore
ndicates the best agreement with experimental data while minimizing the risk of
ver  ﬁtting. In addition, a corrected AIC (AICc) was  applied to adjust for a small
umber of data points (Kletting and Glatting, 2009).
.3. Sensitivity analysis
Sensitivity analysis and parameter identiﬁability were performed to identify the
ost important and sensitive parameters with respect to the blood/plasma AUC for
he  case study chemicals according to Soetaert and Petzoldt (Soetaert and Petzoldt,
010; Soetaert, 2010) prior to their optimization.
In local sensitivity analysis (Eq. (1)), all parameters were evaluated individually
n a very small region close to their nominal value. A parameter value divided by
he  average of simulated outputs was used as a scaling factor (SF).
. = f (x, u, ) y = g(x, ) Sij =
(
j0
SF
)
∂yi
∂j
|=0 (1)
L1 =
∑∣∣Sij∣∣
N
L2 =
√∑
(S2
ij
)
N
(2)
 = 1√
min(EV
[
Tˆ
S ·
ˆ
S
] (3)here y is vector of function outputs for a speciﬁc variable; x is vector of state
ariables;  is vector of parameters (0 parameter estimate); u is vector of inputs; N
s  number of time points; Sˆ is the columns of the sensitivity matrix that correspond
o the parameters included in the set; EV is estimation of the eigenvalues.compartments in PBTK3.
The following kinetic and compound-speciﬁc parameters were analyzed: GI
tract absorption rates (Diss (or Dt), kastm, kaSI, kaLI, kelLI, kmax, kmin), liver metabolic
rates (vmax, km, Kmet), skin absorption parameters (Dsc, Dve, Dhf,  kaform, kahf, PCsc,
PCscve, PChf), blood-to-plasma ratio and tissue-to-blood partition coefﬁcients: PCliv,
PCadp, PCppt, PChpt, PCkid, PClng, PCgit, PCskn.
The higher the absolute sensitivity value, the more important is the parameter.
These sensitivity functions are collapsed into summary values (L1 and L2 are used
as  selection criteria) (Eq. (2)). Based on the sensitivity functions of blood AUC to
selected parameters, the identiﬁability of a set of parameters to be ﬁne-tuned by cal-
ibration is then calculated. As a rule of thumb, a collinearity value () less than about
20 means “identiﬁable” (in general, when the collinearity index exceeds 20, the lin-
ear dependence is assumed to be critical (Eq. (3)) (Brun et al., 2001; Omlin et al.,
2001). The collinearity is a measure of approximate linear dependence between
sets of parameters. The higher its value, the more the parameters are related. In this
context, “related” means that several parameter combinations may produce similar
values of the output variables.
Monte Carlo simulations were used to quantify the impact of variability and
uncertainty in parameter distributions separately by drawing parameter values
according to a predeﬁned distribution (normally distributed random samples), run-
ning the model with each of these parameter combinations, and calculating the
values of the selected output variables at each output interval.
Optimization was  carried out by applying the Levenberg–Marquardt algorithm
to  nonlinear data ﬁtting (Moré, 1978).
2.4. Quantitative structure–property relationships for dermal absorption
Quantitative structure–property relationships (QSPRs) for dermal penetration
were compiled from the literature. These QSPRs, listed in the supplementary mate-
rial  along with supporting references, comprise: 20 equations for overall skin
permeability coefﬁcient (Kp), 9 for stratum corneum permeability coefﬁcient (Kpsc),
5  for viable epidermis permeability coefﬁcient (Kpve), 10 for stratum corneum/water
partition coefﬁcient (PCsc), 7 for stratum corneum/viable epidermis partition coefﬁ-
cient (PCscve) and 7 for maximal ﬂux (Jmax). All these quantities can be used as input
parameters in PBTK models. The predictions closest to in vitro or in vivo experimen-
tal values (if available) were selected. In case no experimental data were available,
the  median of all predicted results was calculated. As can be seen in the supple-
mentary material, the following physicochemical properties are considered in the
QSPR equations: octanol-water partition coefﬁcient, molecular weight and radius,
molar volume, hydrogen bond acceptors, hydrogen bond donors, melting point, the
number of carbons not involved in a C O bond, molecular refractivity and Abraham
descriptors (linear free energy descriptors).
3. Results
3.1. Parameterization of the PBTK model
3.1.1. Liver metabolism and skin metabolism
Liver metabolism rates were taken from the literature and were
optimized with respect to in vivo blood concentrations for the main
metabolites only. Table 2 shows the values used together with
their reference sources. Metabolism was  either assumed to follow
Michaelis–Menten kinetics (4) or was described by the ﬁrst order
reaction (5).vmax · ClivPCliv
km + ClivPCliv
(4)
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Table 2
Metabolites formed in liver and skin.
Metabolite Organ Metabolite of Metabolic rates Reference
o-HPA Liver Coumarin vmax = BW 12.70; km = 397 Rietjens et al.
(2008)7-HC Liver Coumarin vmax = BW 2.5a; km = 0.277
3-HC Liver Coumarin Kmet = BW 0.001
o-HPAA Liver oHPA vmax = BW 144.84; km = 0.136
o-HPE Liver oHPA vmax = BW 60.928; km = 2.4344
Benzoquinone Liver Hydroquinone vmax = BW0.75.4.8; km = 5 Corley et al. (2000)
Hydroquinone Liver Hydroquinone vmax = BW0.75.60; km = 5
Hydroquinone Hydroquinone vmax = BW 60a; km = 5
Gluthatione Liver Benzoquinone vmax = BW0.75.20; km = 0.5
Benzoquinone Skin Hydroquinone vmax = 0.05; km = 4
Paraxanthine Liver Caffeine vmax = 0.351 BWa; km = 1 Lelo et al. (1986)
and Zandvliet et al.
(2005)
Theobromine Liver Caffeine vmax = 0.0432 BW;  km = 1
Theophylline Liver Caffeine vmax = 0.0072 BW;  km = 1
K
w
p
M
e
w
e
3
p
T
A1,3,7-Trimethyluric acid Liver Caffeine 
a Optimized value.
met · ClivPCliv
(5)
here Cliv is the liver concentration and PCliv is the liver-to-blood
artition coefﬁcient of a substance undergoing metabolism.
In case of skin metabolism (for hydroquinone only),
ichaelis–Menten kinetics was also assumed due to lack of
xperimental data. The equation rates were optimized in such a
ay that metabolism was less than 10% of the applied dose (Corley
t al., 2000; McGregor, 2007; Poet et al., 2010)..1.2. Absorption and distribution parameters
The absorption and distribution parameters for parent com-
ounds are given in Table 3. These parameters include literature
able 3
DME parameters for the three case study compounds.
Parameter Coumarin Hydroquinone Caffeine
Kinetic parameters
Diss [1/h] – – 3.2
Dt [L/h] – 4c –
kastm [1/h] 1.8 0.1 0.2
kaSI [1/h] 0.1 0.75c 1.5
kmax [1/h] 8.16b 2.5 8.16b
kmin [1/h] 0.005b 0.005b 0.005b
kelLI [1/h] 0.06g 0.1f 0.1
Dsc [cm2/h] 2.5e-06 4e-08 1.4e-07e
Dve [cm2/h] 9e-05a 8e-06a 1.5e-05a
Dhf [cm2/h] – – 1.243e-05
kaform [mL/h] 0.22 0.038 0.2
kahf [mL/h] – – 0.153
PCsc 1.65 1 2.5e
PCscve 1.829a 0.8a 0.6a
PChf – – 1
RBP 0.25h 0.15h 0.28–0.35d
% of hair follicles in skin (nf) – – 20
Tissue -to-blood partition coefﬁcients
PCliv 2.38i 0.8c 4.25i
PCppt 0.355i 0.8c 0.995i
PChpt 2.09i 0.8c 1i
PCskn 0.68i 0.8c 1i
PClng 0.51i 0.68c 1.23i
PCkid 2.08i 0.71c 3.76i
PCgit 0.62i 0.67c 1.49i
PCadp 1.24i 0.8c 0.68i
a Estimated by QSPRs.
b Loizou and Spendiff (2004).
c Corley et al. (2000).
d Newton et al. (1981).
e Hansen et al. (2008).
f OECD SIDS (1996).
g Ford et al. (2001).
h Predicted by ADMET Predictor (https://www.simulations-plus.com/).
i Schmitt (2008).
(
(Kmet = 0.001 BW
and optimized values. The literature values comprise: stom-
ach emptying rate, absorption rates (diffusion coefﬁcient in
stratum corneum for caffeine, small intestine absorption rate for
hydroquinone, etc.) and tissue-to-blood partition coefﬁcients for
hydroquinone. QSPRs (listed in the supplementary material) were
used to calculate median predicted values of diffusion coefﬁcients
in viable epidermis and partition coefﬁcients between stratum
corneum and viable epidermis. The following parameters were
optimized with respect to blood/plasma concentrations:
a) coumarin: oral data: stomach absorption rate (kastm), small
intestine absorption rate (kaSI), metabolic rate to 7-HC (vmax);
dermal data: diffusion coefﬁcient in stratum corneum (Dsc), par-
tition coefﬁcient stratum corneum/vehicle (PCsc), formulation
rate intake (kaform).
b) hydroquinone: oral data: stomach absorption rate (kastm),
kinetic constant of stomach emptying rate to small intestine
(kamax), metabolic rate to hydroquinone-glucuronide (vmax);
dermal data: diffusion coefﬁcient in stratum corneum (Dsc), pari-
tion coefﬁcient stratum corneum/vehicle (PCsc), formulation rate
intake (kaform).
(c) caffeine: oral data: dissolution rate from a tablet (Diss), stom-
ach absorption rate (kastm), small intestine absorption rate
(kaSI), metabolic rate to paraxanthine (vmax); dermal data:
diffusion coefﬁcient in hair follicles (Dhf), parition coefﬁcient
follicles/vehicle (PChf), formulation rate intake in skin (kaform)
and hair follciles (kahf).
3.2. PBTK model simulations and goodness-of-ﬁt statistics
Simulated concentration–time proﬁles in blood or plasma gen-
erated by the PBTK3 model following oral and dermal absorption
are presented in Fig. 4 for coumarin, Fig. 5 for hydroquinone, and
Fig. 6 for caffeine. Experimental data (Exp. Data) are added to the
plots together with reference sources. Simulations were carried out
either for published individual or group mean data. In the latter
case, a so called mean subject was  built based on the mean physio-
logical information provided and used in the model optimization.
Three statistical criteria, the coefﬁcient of determination (R2),
mean squared error (MSE) and Akaike’s Information Criterion (AIC)
(Kletting and Glatting, 2009), which were used to compare the sim-
ulation performance of the models, are given in Tables 4 and 5.
This comparison was made for the oral and dermal simulation sep-
arately.3.3. Sensitivity analysis
For coumarin, the AUC of simulated blood/plasma is more sen-
sitive to kinetic parameters compared to tissue-to-blood partition
M.  Gajewska et al. / Toxicology Letters 227 (2014) 189–202 195
 (1) (R itschel  et  al., 1977)      (2)  (Ford  et al., 20 01) 
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Gig. 5. Simulations of hydroquinone blood concentrations after oral administratio
mean” volunteer (right) (2-column).
oefﬁcients. Based on the sensitivity function statistics and Monte
arlo simulations, the most sensitive parameters are found to be
ntestine absorption rates (ka , ka ), skin absorption rates (D ,LI SI sc
ve, kform) and coumarin metabolic rate to 7-HC. The most sensi-
ive partition coefﬁcients are PCgit, PCppt and PClng (oral model) and
Cppt, PChpt and PClng (dermal model).
able 4
oodness of ﬁt: oral model.
Compound BW [kg] PBTK3 
MSEa R2b
Coumarin 70 1.245e-05 86.736 
46  2.356e-05 80.369 
68  3.149e-05 83.245 
87.7  4.091e-06 96.367 
Hydroquinone 69 6.568e-05 93.225 
Caffeine 83  0.450 90.867 
65  1.828 20.923 
65  1.422 38.316 
69  0.8117 85.280 
a Mean squared error.
b Coefﬁcient of determination, R-squared.
c Akaike’s Information Criterion with the correction for a small number of data points ( volunteer (left) and plasma concentrations following dermal absorption for the
For hydroquinone, both oral and dermal absorptions tissue-
to-blood partition coefﬁcients show lower sensitivitity to
blood/plasma AUC than kinetic parameters. As expected, the
most sensitive parameters are GI tract absorption rates (kmin,
kastm, Dt),  skin absorption rates (Dsc, Dve, kform) and hydroquinone
metabolic rate to hydroquinone glucuronide. Among the most
PBTK1
AICcc MSEa R2b AICcc
−95.325 1.234e-05 86.855 −96.477
−90.861 3.514e-05 70.727 −89.154
−115.407 8.433e-05 55.129 −108.688
−133.774 2.272e-05 79.822 −120.491
−83.569 5.430e-05 94.398 −85.978
−41.3517 4.158 15.560 −18.376
−18.964 7.462 −222.691 −7.101
−24.4098 4.078 −76.849 −15.7049
−34.268 9.515 −72.567 −8.443
Kletting and Glatting, 2009).
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Gig. 6. Simulations of caffeine plasma concentrations following oral (1–4) and de
hereas plots 2, 3 and 5 are mean group data (2-column).
ensitive partition coefﬁcients are: PCppt, PCadp, PClng (oral model)
nd PClng, PCppt, PCadp (dermal model).
For caffeine and the case of oral administration, tissue-
o-blood partition coefﬁcients show comparable sensitivity to
inetic parameters in terms of blood/plasma AUC; however, lower
ensitivity is observed in the case of dermal absorption. The
ost sensitive kinetic parameters are caffeine metabolic rate to
araxanthine (vmax), skin absorption rates (Dsc, Dve, Dhf) and
able 5
oodness of ﬁt: dermal model:.
Compound BW [kg] PBTK3 PBTK1 
MSEa R2b AICcc MSEa
Coumarin 78 1.274e-05 88.973 −123.225 1.009e-
76  1.084e-04 59.587 −103.959 1.029e-
91  1.381e-05 81.902 −122.499 9.633e-
Hydroquinone 69 1.292e-05 92.862 −67.192 4.938e-
Caffeine 75 9.565e-07 91.052 −163.465 2.305e-
a Mean squared error.
b Coefﬁcient of determination, R-squared.
c Akaike’s Information Criterion with the correction for a small number of data points ((5, bottom left) administration. Plots 1 and 4 show simulated data of individuals
blood-to-plasma ratio. The most sensitive partition coefﬁcients
are: PCadp, PCppt, PCkid (oral model) and PClng, PCadp, PCppt (dermal
model).3.4. QSPR predictions of dermal absorption
A compilation of published in vitro, in vivo and QSPR predic-
tions of properties related to skin penetration is given in Table 6.
PBTK2
R2b AICcc MSEa R2b AICcc
04 12.658 −106.809 4.379e-05 62.108 −112.971
04 61.618 −106.633 3.096e-05 88.455 −116.090
05 −26.223 −107.229 4.857e-05 36.359 −112.037
05 72.722 −61.008 3.221e-05 82.209 −62.797
05 −115.627 −134.960 1.671e-06 84.367 −159.227
Kletting and Glatting, 2009)
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Table  6
Comparison with QSPR-predicted and in vitro/in vivo experimental parameters.
Kp Kpsc Kpve PCsc PCscve Jmax %Abs
Coumarin
in vitro 0.011a 0.009a – – – 0.172a 64.4a
in vivo – – – – – – 62.4b
QSPRs 0.0025 0.003 0.020 4.530 1.829 0.0018 –
Hydroquinone
in  vitro 2e-05a 9.33e-06a – – – 0.807a –
in  vivo – – – – – – 45.3c
QSPRs 0.001 0.0025 0.0017 2.113 0.800 0.0012 –
Caffeine
in  vitro 0.003a – – – – 7.006a 69.4a
in vivo 1.80e-04a – – – – – 60.9a
QSPRs 1.05e-04 3.16 e-04 0.0032 0.864 0.600 0.0011
a EDETOX database http://edetox.ncl.ac.uk/.
b Ford et al. (2001).
c Wester et al. (1998).
Table 7
Rat simulated blood and liver AUC and Cmax for the parent compound and toxic metabolite following NOAEL doses.
Substance Rat oral NOAEL dose
[mg/kg BW]
AUC liver [mg/L/h] AUC blood [mg/L/h] Cmax liver [mg/L] Cmax blood [mg/L]
Coumarin (O-HPA) 10, 50 2.214, 26.773
(0.0171, 0.130)
0.326, 3.760
(0.0009, 0.0065)
8.241, 138.442
(0.062, 0.511)
0.450, 6.389
(0.00098, 0.0077)
0.08
4.72
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NHydroquinone
(Benzoquinone)
20  0.819 (0.029) 
Caffeine 10.1 245.285 
he table shows predictions closest to experimental values for
verall skin permeability coefﬁcient (Kp) and stratum corneum per-
eability coefﬁcient (Kpsc). For the remaining properties, median
alues were calculated, excluding outliers. In addition, the last col-
mn  shows literature ﬁndings on total absorption percentage in
kin (%Abs). For all three substances, the predictions of skin per-
eation coefﬁcients are close to available experimental values,
nd therefore so are the median values. Slight errors in estimat-
ng the permeability/partition coefﬁcients and maximal ﬂux may
rise from the use of water as an application vehicle in tested
ubstances for which QSPR models have been derived. Therefore,
alibration of the values is necessary if in vivo dermal data are avail-
ble. Based on the results for coumarin, hydroquinone and caffeine,
he QSPRs prove to be a useful alternative to in vivo skin penetra-
ion experiments as they give easily generated predictions close to
he observed values and can be taken as suitable starting values
or the absorption parameters in the PBTK model. The diffusion
nd partition coefﬁcients in stratum corneum, were selected for
ptimization with respect to experimental blood data to provide
 better simulation of the in vivo absorption as these parameters
re more dependent on the type of vehicle.
.5. Interspecies extrapolation
The rat PBTK model for oral absorption for the three substances
as a simple structure (Rietjens et al., 2008) with a ﬁrst order rate
f absorption in the GI tract, whereas, the human PBTK 3 model
ncludes sub-compartments as described above. Table 7 shows the
at PBTK model results in terms of the simulated AUC and Cmax
alues at experimentally determined NOAEL doses (application
able 8
OAEL doses extrapolated to human via PBTK model.
Coumarin (O-HPA) 
Extrapolated human
oral NOAEL
[mg/kgBW/day]
AUC liver: 3.9, 11 (16, >100) 
AUC  blood: 3.1, 8.5 (22, >100) 
Cmax liver: 4.7, 40.5 (75, >100) 
Cmax blood: 3.1, 13.5 (60, >100) 1 (0.0035) 1.037 (0.0342) 0.056 (0.0028)
8 123.105 1.867
via gavage). Liver and blood concentrations of the parent com-
pound and its main toxic metabolite were examined. The absolute
doses applied in the human PBTK model that give AUC  and Cmax
values in blood and liver comparable to the rat results were esti-
mated (Table 8). Out of these results, the lowest value was chosen
and assumed to be the extrapolated human NOAEL value, that is,
8.5 mg/kgBW for coumarin, 1.9 mg/kgBW for hydroquinone, and
2.1 mg/kgBW for caffeine based on the parent compound Cmax or
AUC in blood. AUC/Cmax values of toxic metabolites were found to
show internal concentrations comparable to those in rat at much
higher external doses. The dose conversion of coumarin via o-HPA
in blood and liver by the PBTK model at 50 mg/kgBW was found
to be very high (the external dose would need to be more than
100 mg/kgBW, therefore it is indicated as higher than 100 in the
table). Due to this fact and resulting high NOAEL dose extrapolated
to human level, 10 mg/kg BW (dog NOAEL value) was  addition-
ally considered and extrapolated to the value of 3.1 mg/kgBW.
High nonlinearity in results (AUC and Cmax values) was observed
when simulating external doses of 10 and 50 mg/kgBW in rats. This
non-linearity could arise for several reasons including: a) wrongly
assumed unchanged and constant ﬁrst rate of absorption from the
rat GI tract and interspecies differences in absorption; b) higher
delivery of a parent compound to liver than its metabolic clearance.
3.6. Oral to dermal extrapolationThe application conditions, concentrations and vehicles
(coumarin: 2 mg/mL  in ethanol; hydroquinone: 16 mg/mL in
cream; caffeine: 4.562 mg/mL in ethanol/propylene glycol) for
RtR extrapolation were chosen in accordance with the literature
Hydroquinone (Benzoquinone) Caffeine
AUC liver: 16 (28) AUC  liver: 9
AUC blood: 2.4 (3.1) AUC  blood: 2.1
Cmax liver: 13 (24) Cmax liver: 30
Cmax blood: 1.9 (2.7) Cmax blood: 4.2
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Table 9
Internal concentrations predicted by oral-to-dermal extrapolation at oral NOAEL doses.
Substance AUC liver AUC blood Cmax liver Cmax blood
Oral Dermal Oral Dermal Oral Dermal Oral Dermal
Coumarin (O-HPA) 1.222 (3e-05) 5e-02 (1e-06) 0.322 (1e-05) 0.174 (4e-07) 3.592 (1e-04) 8e-03 (2e-07) 0.449 (1e-05) 0.030 (6e-08)
Hydroquinone (benzoquinone) 0.082 (0.002) 0.026 (6e-04) 0.062 (0.002) 0.532 (6e-04) 0.091 (0.002) 6e-04 (1e-05) 0.045 (0.002) 0.013 (1.64e-05)
Caffeine 29.395 26.735 4.201 8.162 7.434 0.946 0.800 0.285
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QFig. 7. Oral and dermal human exposure to coumarin (top, left), hydroqu
ource used in the calibration step with a slight modiﬁcation of
xposure time (2–6 h) and exposed skin area (896 cm2), in order
o be consistent for all three substances. As the absolute amount
f dose applied refers to estimated NOAEL values, the volume of
ehicle had to be increased to ensure unchanged concentrations
nd consequently the exposed skin area is larger. In the case of
oumarin study, only the dose of 3.1 mg/kg BW could be extrap-
lated (from the dog NOAEL value of 10 mg/kg BW/day) under
ealistic conditions. Use of the rat NOAEL value (50 mg/kg BW/day)
xtrapolated to the human (8.5 mg/kg BW)  would require very
igh vehicle volume to maintain the formulation concentration of
 mg/kg BW applied on the skin. Table 9 provides Cmax and AUC
esults for blood and liver after oral and dermal absorption. Model
imulations for the two exposure routes and parent compounds
only) are presented in Fig. 7.
. Discussion
In this study, all steps involved in the application of PBTK mod-
lling for RtR extrapolation (to derive dermal threshold levels from
ral values) were made. First, the PBTK model parameters were cal-
brated with respect to available in vivo literature data, the role of
SPR predictions was evaluated for skin penetration, and then the(top, right) and caffeine (bottom) at single oral NOAEL doses (2-column).
best model structure was selected to simulate the ADME proﬁles of
coumarin, hydroquinone and caffeine.
Finally, the selected PBTK model was used for interspecies (rat
to human) extrapolation and to calculate oral and dermal internal
concentrations at the external (oral NOAEL) doses under strictly
speciﬁed conditions.
Calibration was performed using in vivo blood/plasma con-
centrations of either a single healthy volunteer or mean group
results published in the literature. Except for caffeine, the PBTK
model could not be validated against different experimental data,
which means the applicability domains of the coumarin and hydro-
quinone models are less certain. In addition, absorption parameters
were optimized for a given experimental design (vehicle and
administration type, skin site, etc.) and metabolic/elimination rates
were subject-speciﬁc.
Based on the calibrated parameters in this work, within the
investigated dose ranges, coumarin shows the highest absorption
rate from stomach and diffusion rates within the skin layers. Hydro-
quinone is quickly absorbed from the small intestine. Caffeine
shows the highest partitioning in the stratum corneum (the most
limiting absorption step) and the viable epidermis.
Reﬁned PBTK3 model was compared with the two  simpler
models (PBTK 1 and 2) in simulating blood/plasma concentrations
with respect to available literature in vivo data. The coefﬁcient of
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etermination (R2), mean squared error (MSE) and Akaike’s Infor-
ation Criterion (AIC) (Kletting and Glatting, 2009) were used as
ecision criteria. As the statistics in Tables 4 and 5 show, the PBTK3
odel structure (with sub-compartments in the absorption stage
herefore with more parameters to determine) is better in most of
he instances (7/9 in oral and 4/5 in dermal absorption), as indi-
ated by the lower AICc value whenever individual or mean data
re available for the same substance. PBTK1 has the advantage of
ewer parameters to calibrate and can easily be set for a given
ubject but when applied to a different one, the model does not
how equally good predictions (e.g. coumarin oral data). In the
ermal coumarin experiment, PBTK1 does not give good results,
BTK2 is close to PBTK3 in predictions, but still PBTK3 performs
he best. In the hydroquinone oral and dermal experiments, all
odel structures seem to be good candidates; however in this case
here is no comparison between different subjects. The availability
f many oral experimental data for caffeine makes it a good test
ubstance for choosing the best model. In addition, different types
f dosing were considered, either pure caffeine or its mixture with
erbs/substances. PBTK1 does not perform well either in the case
f pure caffeine or in case of the mixture. PBTK3 gives good predic-
ions for pure caffeine in a gelatin coating (Lelo et al., 1986; Newton
t al., 1981) but performs poorly when applied to the data obtained
n the second study (Csajka et al., 2005). It seems likely that either
BTK3 does not work well when applied to mixtures or the experi-
ental results were more variable due to population effects (e.g. use
f contraceptives) which cannot be easily captured by the present
BTK model. In the dermal model the inclusion of the hair follicles
ompartment, in accordance with the experimental design (Otberg
t al., 2008), helps obtaining better prediction performance. How-
ver, PBTK2, without this compartment, gives also sufﬁciently good
esults (R-squared, AICc, MSE). Based on these observations, it is
oncluded that PBTK3 is the best model for the chosen substances
nd can be used in further applications with higher reliability.
Due to lack of realistic acute toxicity data, rat NOAEL doses
which are based on repeated dose experiments) were used in
his study as a surrogate. The rat values were extrapolated to
uman level prior to RtR extrapolation. For the sake of conser-
ative selection, the lowest human exposure doses giving similar
nternal concentrations, either in terms of Cmax or AUC, to those
alculated by the rat PBTK, model were chosen. These internal con-
entrations refer to the parent compound, not a toxic metabolite
because in humans the metabolites show internal concentrations
hat are comparable to those of the rat at much higher external
oses). Assuming that the toxic effects of a parent compound are
elatively low (if any, including caffeine), no further correction of
xtrapolated doses with respect to toxicodynamics was  made, even
hough this has been suggested by some authors (Bessems and
eraets, 2013). More simplistic than the use of PBTK modelling,
uman equivalent doses can also be calculated according to Eq. (6)
Reagan-Shaw et al., 2008):
ED
[
mg
kgBW
]
= NOELRAT ·
KmRAT
KmHUMAN
(6)
here KmRAT ≈ 6 and KmHUMAN ≈ BWBSA
This approach gives the following results: 1.51 mg/kgBW
or coumarin (2 times lower than the PBTK model result);
or 3.24 mg/kgBW for hydroquinone (1.5 times higher); and
.57 mg/kgBW for caffeine (1.3 times lower). There is a clear dif-
erence in both scaling approaches; however it is only the PBTK
odel that considers differences in biochemical processes between
pecies (especially metabolism) and is thus the more reliable
pproach.
In order to calculate dermal safe limits for the three substances,
he effect of varying absolute dermal dose on AUC and Cmax in blood
as investigated. The surface area of exposed skin was  increasedtters 227 (2014) 189–202 199
proportionately with the applied dose. The diffusion coefﬁcients
were not changed from the values determined in the calibration
step for speciﬁc skin sites although the exposed area had to be
increased. This is a limitation in the extrapolation, as is the lack of
skin absorption data for doses close to the investigated levels. First,
dermal exposure levels at NOAEL doses were translated to inter-
nal concentrations via the PBTK model and compared with those
derived from oral exposure. Then, a cycle of dermal exposure sim-
ulations was performed within a range of external absolute doses to
establish the dermal threshold value. In the case of hydroquinone,
the dermal doses used for simulations were from 1/10 to 5 times
the oral NOAEL value indicating a dermal threshold value based on
AUC in blood that is 9 times lower than the oral NOAEL dose applied
to a skin surface area of 896/9 cm2 (2 h of exposure). However, oral
Cmax values were always higher. For caffeine, doses ranging from
1/5 to 5 times the oral NOAEL value were simulated. At the high-
est dose, the dermal Cmax in blood was close to the oral one but
still slightly lower. The dermal threshold value based on the AUC
in blood was 2 times lower than the oral NOAEL dose applied to a
skin surface area equal to (448.2)/2 cm2 (2 h of exposure). Coumarin
simulations were carried out for dermal doses from 0.5 to 5 times
the oral NOAEL. The dermal safe limit based on coumarin AUC in
blood (6 h of exposure) was 1.8 times higher than the oral NOAEL
dose applied to a skin area of (1.8896) cm2. The same investiga-
tions were carried out for liver Cmax and AUC- calculated values for
the three substances, but matching of rat internal concentrations
would require higher external doses than in case of blood.
5. Conclusions
The use of GI and dermal sub-compartments in the PBTK model
gives a better simulation of absorption for the three cosmetic ingre-
dients than a simple model structure. However, the parameters
estimated for pure substances may  not apply to mixtures. For the
three substances studied, QSPR predictions provide a reliable alter-
native to in vivo dermal penetration experiments, which can be
used as reliable input parameters to the dermal PBTK model. Inter-
species extrapolation by PBTK modelling gives different results
compared with a simple scaling to the human equivalent dose,
which takes into account body weight and surface area only. When
the same absolute dose is applied orally and dermally, different
concentration–time proﬁles in blood and liver are obtained. Under
deﬁned exposure conditions, oral-to-dermal extrapolation at oral
NOAEL values indicates that the dermal AUC in blood is higher than
the corresponding oral values for hydroquinone and caffeine, and is
only slightly lower in the case of coumarin. This indicates that, for
a ﬁxed external dose, oral exposure does not always give a higher
internal concentration than dermal exposure, especially in the case
of low absolute doses.
This study illustrates a strategy for the oral-to-dermal extrapola-
tion of toxicity data based on PBTK modelling using three cosmetic
ingredients as case study compounds. This modelling framework
could be used to guide the generation of additional experimental
data to reﬁne the PBTK models and extend their applicability, with
the ultimate aim of applying the models in chemical risk assess-
ment.
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ppendix A.
PBTK 1: GI tract: 1 compartment with ﬁrst order rate of absorp-
ion
f(t > tlag)
dAabs,GI
dt
=  −kaabs,GI · Aabs,GI else
dAabs,GI
dt
= 0 (A1.1)
here tlag is a time lag of absorption in the GI tract.
PBTK 3: GI tract: sub-compartments: stomach content and tis-
ue, small and large intestine content and absorbed quantity
Stomach content:
dAstm,cont
dt
= Drt − kastm · Cstm,cont − kGIT · Astm,cont (A1.2)
ith Cstm,cont = Astm,contVstm , kGIT =
kmax
(1+kmin·Cstm)
and
admin. via drinking: Drt = Dt · Cdose and Cdose =
Dose
Vdrink
, Astm,cont(t = 0) = 0
admin. via gavage: Drt = 0 and Astm,cont(t = 0) = Dose
admin. via coated tablet: Drt = Diss ·
dAstm,cont,diss
dt and Astm,cont,diss(t = 0) = dose, Astm,cont(t =
0) = 0
Stomach tissue
dAstm
dt
= kastm · Cstm,cont + fra · fgit ·
(
Cart − Cstm
PCstm
)
,
Astm(t = 0) = 0, Cart = Aart
Vart
, Cstm = Astm
Vstm
(A1.3)
Small Intestine lumen and absorbed quantity
dASI,lumen
dt
= kGIT · Astm,cont − (kaSI + flowLI) · CSI,lumen,
ASI,lument(t = 0) = 0, CSI,lumen =
ASI,lumen(
3
4 · Vint
) (A1.4)
dASI
dt
= kaSI · CSI,lumen + frb · fgit ·
(
Cart −
CSI,
PCgit
)
,
ASI(t = 0) = 0, CSI =
ASI(
3
4 · Vint
) (A1.5)
Large Intestine lumen and absorbed quantity:
dALI,lumen
dt
= flowLI · CSI,lumen − (kelLI + kaLI) · CLI,lumen,
ALI,lumen(t = 0) = 0, CLI,lumen =
ALI,lumen(
1
4 · Vint
) (A1.6)
dALI
dt
= kaLI · CLI,lumen + frc · fgit ·
(
Cart − CLIPCgit
)
,ALI(t = 0) = 0, CLI =
ALI(
1
4 · Vint
) (A1.7)tters 227 (2014) 189–202
PBTK 1: Skin: 1 compartment with ﬁrst order rate of absorption
if(t > tlag)
dAabs,skn
dt
= −kaabs,skn · Cabs,skn else
dAabs,skn
dt
= 0,
Cabs,skn =
Aabs,skn
Vabs,skn
, Vabs,skn = Area · L (A1.8)
where tlag is a time lag of absorption in the skin.
PBTK 2: Skin: 2 compartments: one with Fickian diffusion
(E = stratum corneum + viable epidermis)  and one with blood mix.
dCAbs,E,j
dt
≈ −qAbs,E,j+1 − 2 · qAbs,E,j + qAbs,E,j−1
( LEN )
− BioCAbs,E,j
VAbs,E,j
;
j = 1 : N, CAbs,E,j =
AAbs,E,j
VAbs,E,j
(A1.9)
where: qAbs,E,j = −DAbs,E,j ·
CAbs,E,j+1−2·CAbs,E,j+CAbs,E,j−1(
LAbs,E
N
) ; j = 1 : N
If skin metabolism occurs, it is assumed to follow
Michaelis–Menten kinetics:
BioCAbs,E,j =
vmaxn,j ·CAbs,E,j
kmn+CAbs,E,j otherwise BioCAbs,E,j = 0
Initial and boundary conditions:
CAbs,E(t = 0)|0≤y≤LE = 0
dCAbs,E
dt
(t > 0)|x=0 = kaform · Cform
CAbs,E(t > 0)|y=LE = PCskn · Cskn
CAbs,E(t > 0)|x=0 = PCE · Cform
where PCskn is skin-to-blood partition coefﬁcient and PCE is a par-
tition between E and vehicle.
Dermis and Mix  with the blood:
dAskn
dt
= fskn ·
(
Cart − Cskn
PCskn
)
+ qAbs,skn,j=N · Area, Askn(t = 0) = 0
(A1.10)
PBTK 3: Skin: sub-compartments: skin surface, stratum corneum,
viable epidermis,  hair follicles
Skin surface:
dCform
dt
= DesRate − AbsRate − EvapRate Cform =
Aform
V0,appliedForm
(A1.11)
or(t ≤ tappl)AbsRate = −(kaform · Cform + kahf · Cform)
and for(t > tappl)AbsRate = 0 (A1.12)
where tappl is the application time of a formulation. We  assume
that the deposition rate is instantaneous (DesRate = 0).
Evaporation of a solute (EvapRate) is calculated for volatile sub-
stances (here vehicles) according to (Tibaldi et al., 2011):
EvapRate = −kevp
TL
(A1.13)
For a vehicle (solvent) this evaporation is quantiﬁed in terms ofdVappliedForm
dt
= − kevp · Area
1000 · form
VappliedForm(t = 0) = V0,appliedForm
(A1.14)
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where
kevp =
ˇ · MW · Vp
R · T · 10
[
mg
h · cm2
]
 ˇ = 0.0111 · 
0.96
air
· D0.19g
0.15 · X0.04
here  ˇ is the mass transfer coefﬁcient in vapour phase (m h−1),
W the molecular weight, Vp the vapour pressure of the liquid at
kin temperature (Pa), R the gas constant in J mol−1 K−1, T the skin
emperature (Assumed to be 303 K), Vair the velocity of air (at work-
laces it ranges from 0.3–0.6 m s−1), Dg the diffusivity of the liquid
n gas phase (range: 0.03 to 0.06 m2 h−1), the kinematic viscosity
f air (Literature value of 0.054 m2 h−1), X the length of evapora-
ion area in the direction of air stream, TL a thickness of applied
ubstance layer (cm), Area the application area (cm2) and ıform the
ensity of solvent (g cm−3).
Stratum Corneum (SC):
dCSC,i
dt
≈ −qSC,i+1 − 2 · qSC,i + qSC,i−1(
Lsc
N
) ; i = 1 : N, CSC,i = ASC,iVSCi
(A1.15)
where qSC.,i = −Dsci ·
CSC,i+1−2·CSC,i+CSC.,i−1(
Lsc
N
) ; i = 1 : N
Initial and boundary conditions:
CSC (t = 0)|0≤x≤LSC = 0
dCSC
dt
(t > 0)|x=0 = kaform · Cform
DSC ·
dCSC
dx
(t > tappl)|x=0 = 0
CSC (t > 0)|x=0 = PCSC · Cform
CSC (t > 0)|x=LSC = PCSCVE · CVE
Viable Epidermis (VE):
dCVE,j
dt
≈ −qVE,j+1 − 2 · qVE,j + qVE,j−1(
Lve
M
) − BioCVE,j
VVE,j
; j = 1 : M,
CVE,j =
AVE,j
VVEj
(A1.16)
where qVE,j = −DVE,j ·
CVE,j+1−2·CVE,j+CVE,j−1(
LVE
M
) ; j = 1 :
 and BioCVE,j =
vmaxm,j ·CVE,j
kmm+CVE,j (for hydroquinone only)
Initial and boundary conditions:
CVE(t = 0)|0≤y≤LVE = 0
CVE(t > 0)|y=0 =
CSC,i=N
PCSCVE
DSC
dCSC
dx
|x=LSC = DVE ·
dCVE
dy
|y=0
CVE(t > 0)|y=LVE = PCskn · Cskn
Dermis and mix  with the blood:
dAskn
dt
= 3
4
·  fskn ·
(
Cart − CsknPCskn
)
+ qVE,j=M ·
100 − nf
100
·  Area,
Askn(t = 0) = 0, Cskn =
Askn
10−3 · 23 · Vde
(A1.17)
We  assume that the ﬁne skin covers 2/3 of the dermis, whereas
air follicles 1/3 and ¾ of the overall blood ﬂow goes to the ﬁne
kin.
Hair follicles compartment (Bookout et al., 1997):dChf,i
dt
≈ −qhf,i+1 − 2 · qhf,i + qhf,i−1(
Lhf
K
) ; i = 1 : K, Lhf = 388560 · L
(A1.18)tters 227 (2014) 189–202 201
qhf.,i = −Dhfi ·
Chf,i+1 − 2 · Chf,i + Chf.,i−1(
Lhf
K
) ; i = 1 : K
The initial and boundary conditions:
Chf (t = 0)|0≤x≤Lhf = 0
dChf
dt
(t > 0)|x=0 = kahf · Cform
Dhf ·
dChf
dx
(t > tappl)|x=0 = 0
Chf (t > 0)|x=0 = PChf, · Cform
Chf (t > 0)|x=Lhf = PCSkn · Csknhf
Mix  with a blood:
dAskinhf
dt
= 1
4
· fskn ·
(
Cart −
Csknhf
PCskn
)
+ qhf,i=K ·
nf
100
·  Area,
Asknhf (t = 0) = 0, Csknhf =
Asknhf
10−3 · 13 · Vde
(A1.19)
The rest of compartments/tissues are common for PBTK 1, PBTK2
and PBTK 3:
Adipose tissue (adp), highly perfused tissues (hpt) and poorly
perfused tissues (ppt):
dAorg
dt
= forg ·
(
Cart −
Corg
PCorg
)
, Aorg(t = 0) = 0, Cart = Cart
Vart
,
Corg =
Aorg
Vorg
(A1.20)
where org = organ name (adp, hpt, ppt)
Kidney
dAkid
dt
= fkid ·
(
Cart − Ckid
PCkid
)
− CLR · Ckid
PCkid
(A1.21)
Liver
dAliv
dt
= FlGIT + FORMliv + fliv ·
(
Cart − Cliv
PCliv
)
− METliv,
Aliv(t = 0) = 0, Cliv =
Aliv
Vliv
(A1.22)
For a parent compound:
GI tract with1 compartment: FlGIT = dAAbs,GI
GI tract with sub-compartments: FlGIT = fra · fgit · CstmPCgit + frb ·
fgit · CSIPCgit + frc · fgit ·
CLI
PCgit
FORMliv = 0 (rate of formation of metabolites)
Venous blood:
dAven
dt
= fliv ·
Cliv
PCliv
+ fppt ·
Cppt
PCppt
+ fhpt ·
Chpt
PChpt
+ fadp ·
Cadp
PCadp
+ fkid ·
Ckid
PCkid
+ Flskn − f crd · Cven, Aven(t = 0) = 0,
Cven = Aven
Vven
(A1.23)
For dermal absorption only:
Skin with 1 compartment (PBTK1): Flskn = dAAbs,skn
Skin with 2 compartments (PBTK2): Flskn = fskn · CsknPCskn
CSkin with sub-compartments (PBTK3): Flskn = 34 · fskn · sknPCskn +
1
4 ·
fskn ·
Csknhf
PCskn
Plasma quantiﬁcation: Cven,PL =
Aven⁄(0.55 · Vven)
RBP
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where: RBP is blood-to-plasma partition coefﬁcient.
Arterial blood and lungs:
dAlng
dt
= flng ·
(
Cven −
Clng
PClng
)
, Alng(t = 0) = 0, Clng =
Alng
Vlng
(A1.24)
dAart
dt
= f crd ·
(
Clng
PClng
− Cart
)
, Aart(t = 0) = 0 (A1.25)
ppendix B. Supplementary data
Supplementary data associated with this article can be
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014.03.013.
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